Keller Rohrback Investigates the Skyrocketing Cost of Advair
For millions of Americans, the COPD and Asthma medication Advair helps them breathe a little easier; but it does so at an unreasonably high cost. The cost of Advair has jumped dramatically over the past several years. For example, the average wholesale price (AWP) of Advair* has jumped from $410.17 in January of 2013 to $570.38 in January of 2017—an increase of 39%! Americans are also paying dramatically more for this critical drug than most of the rest of the world. But why, and who is profiting?
While drug manufacturers certainly contribute to the price inflation problem, they do not act alone. Rather, manufacturers may collude with pharmacy benefit managers (“PBMs”) to raise a drug’s “list price”—which the PBMs direct consumers to pay—thus reaping outsized profits from people who need drugs like Advair to stay alive.
The high cost of Advair, for which no medically comparable generic form is currently available, needlessly inflicts physical, emotional, and financial harm on patients and their families.
Keller Rohrback L.L.P. serves as lead and co-lead counsel in class action lawsuits throughout the country, including actions asserting RICO, ERISA, and consumer claims against PBMs. With offices in New York, Seattle, Phoenix, Ronan, Oakland, and Santa Barbara, our Complex Litigation Group is proud to offer its expertise to clients nationwide. Our trial lawyers have obtained judgments and settlements on behalf of clients in excess of eighteen billion dollars.
Attorney Advertising. Prior results do not guarantee a similar outcome. Not licensed to practice law in all states. Please refer to our website for details.
*Listed prices are for Advair Diskus 500-50 mcg/dose.